Please login to the form below

Not currently logged in
Email:
Password:

BMS ends development of Alzheimer’s candidate avagacestat

Amyloid-targeting candidate fails to make it to phase III trials

Bristol-Myers Squibb (BMS) has become the latest company to end development of an amyloid-targeting Alzheimer's drug candidate, following the termination of the trial programme for avagacestat.

The pharma company said that results from phase II trials investigating the compound “did not establish a profile that supported advancement to phase III development”, bringing an end to hopes for the drug as a vital breakthrough in Alzheimer's treatment.

Issues with avagacestat's efficacy were noted by BMS as the reason for pulling development, with no new safety issues emerging during the latest analysis of phase II data.

Other researchers will have the opportunity to learn from avagacestat's failings next year, with BMS due to share this phase II data at a scientific forum during 2013.

It is the latest in a number of trial disappointments involving drugs that target amyloid beta, which is deposited in the form of plaque in the brains of people with Alzheimer's.

In August, 2012, Pfizer and Johnson & Johnson ended their programme to investigate bapineuzumab after phase III trials showed it provided no cognitive or functional benefit in patients with mild-to-moderate Alzheimer's disease.

This was shortly followed by an announcement from Lilly that its amyloid-targeting antibody solanezumab failed to show a significant benefit in patients with Alzheimer's disease.

However, both compounds target amyloid plaque once it has already built up, and there are hopes that treatments that target the condition earlier on could be effective.

This include Merck & Co's candidate MK-8931, which recently became the first beta-amyloid precursor protein site-cleaving enzyme (BACE) inhibitor to reach phase II/III development.

The BACE inhibitor class of therapies cut amyloid precursor protein (APP), interrupting the formation of beta amyloid and preventing the formation of the amyloid plaques.
Other companies also pinning their hopes on BACE inhibitors include Lilly, Roche and Eisai.

BMS has not given up on its Alzheimer's programme either, and said it will continue to test the amyloid hypothesis with an investigational gamma secretase modulator in phase I development.

4th December 2012

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

Forecasting for Licensed Compounds
Peter Mansell examines the impact of heavier in-licensing/out-licensing traffic on pharmaceutical forecasting...
When to use patient flow analysis and how to get it right
With the evolution of forecasting models, analysts have more tools at their disposal to accurately forecast drugs and diagnostics....
blog-icon-webinar-richdata.png
Webinar: The right e-detailing content for rich data
Data is the fuel for your digital communication – powering you to not only learn about your customers but communicate more effectively too....

Infographics